Management of Risperidone and Trihexyphenidyl

Addressing the Subtherapeutic Risperidone Dose

• The current risperidone dose of 0.5 mg is likely subtherapeutic and should be increased to at least 2-4 mg/day, while simultaneously tapering and discontinuing trihexyphenidyl to avoid anticholinergic burden and cognitive impairment 1, 2

Drug Interaction Considerations

• Both vilazodone and risperidone are metabolized by CYP2D6, which may lead to altered plasma concentrations and increased side effects 1
• Consider that the patient may be a slow CYP2D6 metabolizer if they experience side effects at lower risperidone doses, though this is unlikely given the current subtherapeutic dose 1

Monitoring During Dose Adjustment

• Evaluate for physical illnesses that could mimic or exacerbate psychiatric symptoms before attributing breakthrough symptoms solely to inadequate dosing 2
• Allow 14-21 days at each dose level before determining inadequate response and increasing further 2

Common Pitfalls to Avoid

• Do not ignore the possibility of CYP2D6-mediated interactions - if unusual side effects occur at low doses, consider pharmacogenetic testing 1